Mathilde Delebarre1,2, Aude Tiphaine3,4, Alain Martinot3,5, François Dubos3,5. 1. Univ. Lille, CHU Lille, Pediatric Emergency Unit & Infectious Diseases, Lille, France. mathilde.delebarre@chru-lille.fr. 2. Univ. Lille, EA2694, Public Health, Epidemiology and Quality of Care, Lille, France. mathilde.delebarre@chru-lille.fr. 3. Univ. Lille, CHU Lille, Pediatric Emergency Unit & Infectious Diseases, Lille, France. 4. CHU Bordeaux, Pediatric Hematology-Oncology Unit, Bordeaux, France. 5. Univ. Lille, EA2694, Public Health, Epidemiology and Quality of Care, Lille, France.
Abstract
BACKGROUND: In 2012, new international guidelines for children with chemotherapy-induced febrile neutropenia (FN) were issued, recommending reduced-intensity management strategy based on stratification of infectious risks. Some studies have highlighted practice disparities in different countries and within the same country. Our aim was to assess the current management strategies for the treatment of chemotherapy-induced FN in children in France. PROCEDURE: This survey of all French pediatric oncology-hematology reference centers (n = 30) in late 2012 and early 2013 sent a standardized questionnaire to each center inquiring about their definition of an FN episode, its initial empiric treatment and ongoing management, use of management stratified by risk, and any criteria used for the risk assessment. Each center's management protocol was also analyzed. RESULTS: All French reference centers participated in this survey, completing 88% of the questionnaire items. Definitions of both fever and neutropenia varied between centers. Ten centers used a risk-stratification strategy for initial management. In all, 42 probabilistic first-line antibiotic treatments were identified. After 48 hr of apyrexia, 17 units applied different forms of step-down therapy. CONCLUSIONS: Most French centers already offered some form of reduced-intensity or step-down therapy, although they differed substantially in their management of FN episodes. Risk stratification with validated tools is essential to facilitate the implementation of the international recommendations, which would ultimately help to standardize practices in France.
BACKGROUND: In 2012, new international guidelines for children with chemotherapy-induced febrile neutropenia (FN) were issued, recommending reduced-intensity management strategy based on stratification of infectious risks. Some studies have highlighted practice disparities in different countries and within the same country. Our aim was to assess the current management strategies for the treatment of chemotherapy-induced FN in children in France. PROCEDURE: This survey of all French pediatric oncology-hematology reference centers (n = 30) in late 2012 and early 2013 sent a standardized questionnaire to each center inquiring about their definition of an FN episode, its initial empiric treatment and ongoing management, use of management stratified by risk, and any criteria used for the risk assessment. Each center's management protocol was also analyzed. RESULTS: All French reference centers participated in this survey, completing 88% of the questionnaire items. Definitions of both fever and neutropenia varied between centers. Ten centers used a risk-stratification strategy for initial management. In all, 42 probabilistic first-line antibiotic treatments were identified. After 48 hr of apyrexia, 17 units applied different forms of step-down therapy. CONCLUSIONS: Most French centers already offered some form of reduced-intensity or step-down therapy, although they differed substantially in their management of FN episodes. Risk stratification with validated tools is essential to facilitate the implementation of the international recommendations, which would ultimately help to standardize practices in France.
Authors: Stéphanie Wagner; Eva K Brack; Eveline Stutz-Grunder; Philipp Agyeman; Kurt Leibundgut; Oliver Teuffel; Roland A Ammann Journal: PLoS One Date: 2018-02-20 Impact factor: 3.240
Authors: Max Scheler; Thomas Lehrnbecher; Andreas H Groll; Ruth Volland; Hans-Jürgen Laws; Roland A Ammann; Philipp Agyeman; Andishe Attarbaschi; Margaux Lux; Arne Simon Journal: Infection Date: 2020-06-10 Impact factor: 3.553
Authors: Gabrielle M Haeusler; Robert Phillips; Monica A Slavin; Franz E Babl; Richard De Abreu Lourenco; Francoise Mechinaud; Karin A Thursky Journal: EClinicalMedicine Date: 2020-06-15
Authors: Alexandra Podpeskar; Roman Crazzolara; Gabriele Kropshofer; Petra Obexer; Evelyn Rabensteiner; Miriam Michel; Christina Salvador Journal: Front Pediatr Date: 2022-09-12 Impact factor: 3.569
Authors: Maxime G Zermatten; Christa Koenig; Annina von Allmen; Philipp Agyeman; Roland A Ammann Journal: Sci Data Date: 2019-01-15 Impact factor: 6.444